In 2014, there were about 36.9 million people living with HIV and about 2 million were infected. The virus, which causes AIDS, is commonly spread through sexual activity, and although antiretroviral therapy has turned the once-universally fatal condition into a chronic one, 1.2 million people died as a result of AIDS-related diseases last year.
A University of Georgia researcher has found that low levels of vitamin D may limit the effectiveness of HIV treatment in adults.
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV. Their new study describes four prototype antibodies that target a specific weak spot on the virus.
To combat health disparities in the African-American community, Danelle Stevens-Watkins began research on them. And not only to collect data that could yield important findings, but to test a new way of helping incarcerated men.
In a new look at the groundbreaking iPrEx trial for people at high risk of HIV infection, UCSF researchers have identified strong evidence of efficacy for transgender women when PrEP, a two-drug antiretroviral used to prevent HIV, is used consistently.
Acute kidney injury (AKI) associated with tenofovir disoproxil fumarate (TDF) was prevalent among HIV-infected patients and demonstrated a high morbidity rate in a new center-based study. More than half of patients with TDF-associated AKI did not recover baseline kidney function during follow-up, and about one-third of the patients required dialysis, according to research that will be presented at ASN Kidney Week 2015 November 3–8 at the San Diego Convention Center in San Diego, CA.
After peaking in 2007, AIDS mortality in South Africa has decreased with the widespread introduction of effective antiretroviral therapy, according to updated estimates published in AIDS, official journal of the International AIDS Society. AIDS is published by Wolters Kluwer.
A computer model developed by Johns Hopkins health care delivery specialists predicts that strengthening a handful of efforts to keep people with HIV in lifetime care, along with more rigorous testing, would potentially avert a projected 752,000 new HIV infections and 276,000 AIDS deaths in the United States alone over the next 20 years.
“Decision aids” in the form of informational brochures help get patients talking about their anesthesia and pain relief options, according to a study presented at the ANESTHESIOLOGY® 2015 annual meeting. Shared decision making is critical to a more patient-centered process, as well as helping patients take an active role in their medical decisions.
Analyses of landmark RV144 HIV vaccine study volunteers revealed that those who developed a unique set of vaccine-induced antibodies in combination with a high level of CD4 T-cell responses to the outer portion of the HIV virus, called its envelope gene, correlated with reduced HIV infection.
Early AIDS/HIV medical crusader, Paul O'Keefe, MD, Loyola University Health System, receives Catholic Charities top honor for a lifetime of charitable work.
In this month’s release, find new embargoed research about school connectedness and its relation to student BMI; greater health benefits of living in green housing; and ways in which gender, race, ethnicity and type of insurance can predict HPV vaccination completion.
University of Texas at El Paso (UTEP) researchers have patented a low-cost printer that helps HIV patients living in low-resource settings track the health of their cells.
In a study involving 2,400 men who have sex with men who were also enrolled in the Multicenter AIDS Cohort Study, researchers report that men with HIV who were treated effectively with HIV therapy — defined as no detectable HIV virus in the blood — were the least likely (80 percent less likely) to get infected with HBV over a median follow-up of approximately 9.5 years
An international team of researchers have designed and synthetized a nanometer-scale DNA “machine” whose customized modifications enable it to recognize a specific target antibody.
New iPhone app from Apple is designed to make it easier for large numbers of HIV patients to participate in research. Will enable participants to easily complete tasks or submit surveys right from the app.
A unique molecule developed at Duke Medicine, the University of North Carolina at Chapel Hill and MacroGenics, Inc., is able to bind HIV-infected cells to the immune system’s killer T cells. It could become a key part of a shock-and-kill strategy being developed in the hope of one day clearing HIV infection.
There is little doubt that the Human Immunodeficiency Virus, or HIV, is devastating. More than 1.2 million people in the United States are living with HIV and more than 47,000 people are diagnosed annually. Now, University of Missouri researchers have made a discovery in how specialized proteins can inhibit the virus, opening the door for progress in the fight against HIV and for the production of advanced therapeutics to combat the disease.
Simple melodies help nurses remember medicines for treating HIV in pregnant patients.
Researchers at NYU have conducted a systematic review and meta-analysis of studies characterizing the incidence of the sexual transmission of HCV among HIV-positive MSM. The high reinfection rates and the attributable risk analysis suggest the existence of a subset of HIV-positive MSM with recurring sexual exposure to HCV. Approaches to HCV control in this population will need to consider the changing epidemiology of HCV infection in MSM.
The pioneering work of Dr. Kristen Ries and her physician’s assistant Maggie Snyder —the first Utah health care providers to treat patients with HIV and AIDS in the 1980s —will be chronicled in new oral history and special collections project at the U. An October symposium at the S.J. Quinney College of Law will focus on their central role in the struggle against HIV and AIDS in conservative Utah.
An emerging class of drugs called Smac mimetics may lead to a safe and effective treatment to eradicate HIV.
The fungus Cryptococcus causes meningitis, a brain disease that kills about 1 million people each year. It’s difficult to treat because fungi are genetically quite similar to humans, so compounds that affect fungi tend to have toxic side effects for patients. Now, researchers at the University of Wisconsin-Madison have identified 18 proteins that play a role in spore formation and germination. The findings raises the possibility of preventing the disease by blocking the spores’ germination.
In a new analysis of military health surveillance data during 1990–2013, service members diagnosed with HIV-1 in more recent years have tended to remain on active duty longer than those who became infected in the earlier years of that time period.
In 2006 the Centers for Disease Control and Prevention recommended that most doctors should automatically screen all their patients, including older adults, for HIV even if they don't exhibit any symptoms. New research finds that despite this recommendation, testing among older adults has largely fallen over time.
There may be two new ways to fight AIDS -- using a heat shock protein or a small molecule – to attack fibrils in semen associated with HIV during the initial phases of infection. HIV is most commonly transmitted in semen, which contains amyloid fibrils. These can increase the transmission of HIV by helping the it attach to the membrane surrounding human cells.
People infected with the hepatitis C virus are at risk for liver damage, but the results of a new Johns Hopkins study now show the infection may also spell heart trouble.
A researcher at the University of Warwick has received international recognition for his contribution to AIDS research.
Researchers at University of California, San Diego School of Medicine report that more than one in four female sex workers in two Mexican cities on the U.S. border entered the sex trade younger than age 18; one in eight before their 16th birthday. These women were more than three times more likely to become infected with HIV than those who started sex work as adults.
A recent HIV vaccine trial testing the HIV envelope as an immunogen was unsuccessful for protection against HIV infection. A new study has found that this vaccine selectively recruited antibodies reactive with both the HIV envelope and common intestinal microbes — a phenomenon previously reported by the same investigators to occur in the setting of acute HIV infection.
The Scripps Research Institute has been awarded two grants from the Bill & Melinda Gates Foundation totaling more than $4.5 million to fund new tools to collect and process high-resolution images of HIV proteins interacting with antibodies with goal to develop a vaccine against HIV/AIDS.
Other topics include nursing research, treating hep C and HIV, and more
Researchers at the University of California, School of Medicine found a new combination that effectively treats hepatitis C (HCV) patients co-infected with human immunodeficiency virus type 1 (HIV).
The CrAg Lateral Flow Assay (LFA) a novel, rapid diagnostic test, is playing a crucial role in saving lives all over the world. The CrAg LFA tests for an infection called Cryptococcosis, which kills over 600,000 people every year, primarily in HIV/AIDS patients. Because of the ease-of-use and room temperature storage, the CrAg LFA, developed by IMMY, is the only test capable of bridging the gap between this disease and the life-saving medicine these patients need.
Research with human tissue and cells suggests that genetic variations, in addition to failure to comply with treatment regimens, may account for some failures of an anti-HIV drug to treat and prevent HIV infection.
Scientists from the Florida campus of The Scripps Research Institute have shown that, unlike other antiretroviral therapies, a natural compound called Cortistatin A establishes a near-permanent state of latency and greatly diminishing the HIV virus’ capacity for reactivation.
HIV, or human immunodeficiency virus, is the retrovirus that leads to acquired immunodeficiency syndrome or AIDS. Globally, about 35 million people are living with HIV, which constantly adapts and mutates creating challenges for researchers. Now, scientists at the University of Missouri are gaining a clearer idea of what a key protein in HIV looks like, which will help explain its vital role in the virus’ life cycle. Armed with this clearer image of the protein, researchers hope to gain a better understanding of how the body can combat the virus with the ultimate aim of producing new and more effective antiviral drugs.
Congress needs to immediately lift the ban on federal funding for needle exchange programs to counter the threat of HIV outbreaks among injection drug users like the one that has seen an alarming number of new cases erupt in a single rural Indiana county.
Research published in the Proceedings of the National Academy of Sciences found that some individuals exposed to HIV-1, but who remain uninfected, have a certain pattern of virus-specific immune responses that differentiated them from individuals who became infected.
New research offers further evidence that cocaine use disrupts the immune system, making people who use it more likely to become infected with HIV.
New research led by scientists at The Scripps Research Institute, International AIDS Vaccine Initiative and The Rockefeller University shows in mice that an experimental vaccine candidate designed at TSRI can stimulate the immune system activity necessary to stop HIV infection.
In a finding that furthers the understanding of human immunodeficiency virus (HIV), researchers from Children’s Hospital Los Angeles discovered two locations where a single difference in HIV’s genetic code altered the way the virus infected the cell, thereby influencing the progression of the disease.
Cornell University engineers have created a functional, synthetic immune organ that produces antibodies and can be controlled in the lab, completely separate from a living organism. The engineered organ has implications for everything from rapid production of immune therapies to new frontiers in cancer or infectious disease research.
How most babies are protected from acquiring HIV from their infected mothers has been a matter of scientific controversy. Now researchers at Duke Medicine provide new data identifying an antibody response that had long been discounted as inadequate to confer protection.
In a scientific discovery that has significant implications for preventing HIV infections, researchers at Sanford-Burnham Medical Research Institute have identified a protein that could improve the body’s immune response to HIV vaccines and prevent transmission of the virus.
Researchers at New York University’s Center for Health, Identity, Behavior & Prevention Studies (CHIBPS) sought to identify the factors associated with incident HIV infection among a cohort of racially/ethnically and socioeconomically diverse YMSM.
With the help of a computer program called “Rosetta,” researchers at Vanderbilt University have “redesigned” an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody.
A diabetes drug may have benefits beyond lower blood sugar in patients with HIV. New research from Washington University School of Medicine in St. Louis suggests the drug may prevent cardiovascular problems because it works to reduce inflammation that is linked to heart disease and stroke in these patients. The drug both improved metabolism and reduced inflammation in HIV-positive adults on antiretroviral therapy.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right